Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends.

ABSTRACT: Epigenetic drug discovery field has evidenced significant advancement in the recent times. A plethora of small molecule inhibitors have progressed to clinical stage investigations and are being explored exhaustively to ascertain conclusive benefits in diverse malignancies. Literature precedents indicates that substantial amount of efforts were directed towards the use of epigenetic tools in monotherapy as well as in combination regimens at the clinical level, however, the preclinical/preliminary explorations were inclined towards the identification of prudent approaches that can leverage the anticancer potential of small molecule epigenetic inhibitors as single agents only. This review article presents an update of FDA approved epigenetic drugs along with the epigenetic inhibitors undergoi

SUBMITTER: Nepali K 

PROVIDER: S-EPMC8040241 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature